Latest Breaking News On - Redhill biopharma inc - Page 5 : vimarsana.com

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals

RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D

Share this article TEL AVIV, Israel and RALEIGH, N.C,, Jan. 11, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ( Cosmo ), announced that it had successfully completed their Phase 2 Proof-of-Concept (POC) clinical trial of Rifamycin SV-MMX 600mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).  As part of an exclusive license agreement between RedHill and Cosmo from October 2019 for the U.S. rights to Aemcolo ® (rifamycin), RedHill maintains certain rights, including a right of first refusal, in relation to Rifamycin SV-MMX 600 mg in the U.S.